Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis

Qian Qin(Icahn School of Medicine at Mount Sinai), Che‐Kai Tsao(Mount Sinai Hospital), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Xiaobo Zhong(Icahn School of Medicine at Mount Sinai), Philip Garcia(Icahn School of Medicine at Mount Sinai), Parissa Alerasool(New York Medical College), Amanda Leiter(Icahn School of Medicine at Mount Sinai), Himanshu Joshi(Icahn School of Medicine at Mount Sinai), Tomi Jun(Sema4 (United States)), Mahalya Gogerly-Moragoda(Icahn School of Medicine at Mount Sinai), Emily J. Gallagher(Icahn School of Medicine at Mount Sinai), Vaibhav G. Patel(Icahn School of Medicine at Mount Sinai), William Oh(Women & Infants Hospital of Rhode Island), Anish B. Parikh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Bo Wang(Icahn School of Medicine at Mount Sinai), George Mellgard(Memorial Sloan Kettering Cancer Center)
Discover Oncology
August 12, 2022
10.1007/s12672-022-00538-6
Cited by 12

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Whole-Body Hypothermia for Neonates with Hypoxic–Ischemic Encephalopathy
|New England Journal of Medicine|2005|2.8k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Late-Onset Sepsis in Very Low Birth Weight Neonates: The Experience of the NICHD Neonatal Research Network
|PEDIATRICS|2002|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k